Kalbe Farma Tbk PT

Kalbe Farma Tbk PT

Health CarePharmaceuticals and Biotechnology
  • Price (IDR)2,210.00
  • Today's Change40.00 / 1.84%
  • Shares traded24.29m
  • 1 Year change+33.94%
  • Beta0.5634
Data delayed at least 10 minutes, as of Mar 21 2023 08:14 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Events & Activity

  • KLBF:JKT price moved over -2.70% to 2,160.00
  • KLBF:JKT price falls below 50-day moving average to 2,140.00 at 13:30 BST
  • KLBF:JKT price falls below 50-day moving average to 2,140.00 at 09:24 BST

Key statistics

On Tuesday, Kalbe Farma Tbk PT (KLBF:JKT) closed at 2,210.00, -6.36% below its 52-week high of 2,360.00, set on Feb 13, 2023.
52-week range
1,530.00May 10 20222,360.00Feb 13 2023
Previous close2,170.00
Average volume24.00m
Shares outstanding46.88bn
Free float19.89bn
P/E (TTM)30.46
Market cap103.59tn IDR
EPS (TTM)72.55
Annual div (ADY)35.00
Annual div yield (ADY)1.58%
Div ex-dateMay 31 2022
Div pay-dateJun 22 2022
Data delayed at least 10 minutes, as of Mar 21 2023 08:14 BST.
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
S&P Global Market Intelligence Short Selling Activity © S&P Global Market Intelligence. All rights reserved.
Although S&P Global Market Intelligence has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of S&P Global Market Intelligence on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.